Results 11 to 20 of about 1,177,085 (276)

A Randomized, Controlled Trial of Treat-and-Extend vs. Pro Re Nata Regimen for Neovascular Age-Related Macular Degeneration [PDF]

Frontiers in Medicine, 2022
PurposeTo compare the efficacy and safety of conbercept using a treat-and-extend (T&E) regimen vs. a pro re nata (PRN) regimen in Chinese patients with neovascular age-related macular degeneration (nAMD).MethodsThis was a randomized, multicenter, non-
Huixun Jia, Huixun Jia, Huixun Jia, Huixun Jia, Bing Lu, Bing Lu, Bing Lu, Yuanzhi Yuan, Fei Yuan, Lei Li, Yanping Song, Ao Rong, Minwen Zhou, Minwen Zhou, Minwen Zhou, Fenghua Wang, Fenghua Wang, Fenghua Wang, Fenghua Wang, Xiaodong Sun, Xiaodong Sun, Xiaodong Sun, Xiaodong Sun   +22 more
doaj   +2 more sources

Treat and Extend Regimen of Aflibercept in the Treatment of Type 1 Choroidal Neovascularization Secondary to Chronic Central Serous Chorioretinopathy: Three-year Follow-Up [PDF]

Clinical Ophthalmology
Taras B Kustryn, Oleg S Zadorozhnyy, Illia O Nasinnyk, Alla O Nevska, Kseniia V Troianovska, Nataliya V Pasyechnikova, Andrii R Korol Laser Microsurgery Department, The Filatov Institute of Eye Diseases and Tissue Therapy of the National Academy of ...
Kustryn TB, Zadorozhnyy OS, Nasinnyk IO, Nevska AO, Troianovska KV, Pasyechnikova NV, Korol AR   +6 more
doaj   +2 more sources

The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol [PDF]

International Ophthalmology, 2021
To investigate the adherence rate of neovascular age-related macular degeneration (nAMD) patients in treat-and-extend (TAE) protocol to their anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection (IVI) appointments and to evaluate the functional and anatomical outcomes of the patients who attended and did not attend their IVI ...
Mehmet Orkun Sevik, Aslan Aykut, Gamze Özkan, Volkan Dericioğlu, Özlem Şahin   +4 more
openaire   +3 more sources

External Limiting Membrane Disruption Predicts Long-Term Outcome in Strict Treat-And-Extend Regimen in Neovascular Age-Related Macular Degeneration

Frontiers in Medicine, 2021
The use of anti-vascular-endothelial growth factor agents for neovascular age-related macular degeneration (nAMD) in different treatment schemes is widely common in clinical practice.
Laura Hoffmann, Katja Hatz, Katja Hatz
doaj   +1 more source

Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema [PDF]

Scientific Reports, 2020
AbstractThis study was performed to investigate the efficacy of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema (DME). This prospective, multicentre, interventional, single-arm, 104-week clinical trial included 48 patients with DME visual impairment.
Yu Cheol Kim, Jae Pil Shin, Kang Yeun Pak, Hyun Woong Kim, Min Sagong, Sang Joon Lee, In Young Chung, Sung Who Park, Ji Eun Lee   +8 more
openaire   +3 more sources

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration

International Journal of Retina and Vitreous, 2021
Background To assess the morphological and functional outcome of intravitreal aflibercept following the treat and extend protocol compared to the fixed protocol for treatment of eyes with neovascular age-related macular degeneration.
Alaa Din Abdin, Asem Mohamed, Cristian Munteanu, Isabel Weinstein, Achim Langenbucher, Berthold Seitz, Shady Suffo   +6 more
doaj   +1 more source

Three-year outcome of aflibercept treatment for Japanese patients with neovascular age-related macular degeneration

BMC Ophthalmology, 2020
Background To evaluate the three-year outcome after intravitreal aflibercept injection (IAI) for neovascular age-related macular degeneration (nAMD). Methods Forty-nine treatment-naïve nAMD patients (50 eyes) were enrolled in this prospective study.
Kanako Itagaki, Tetsuju Sekiryu, Akihito Kasai, Yukinori Sugano, Masashi Ogasawara, Masaaki Saito   +5 more
doaj   +1 more source

Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration

International Journal of Retina and Vitreous, 2021
Purpose To investigate the visual and anatomical outcomes associated with treat-and-extend (TAE) regimen of intravitreal (IVT) aflibercept in eyes with treatment naïve neovascular age-related macular degeneration (nvAMD).
Mohamed Kamel Soliman, Nicolas Tuli, Thomas K. Lee, William A. Britton, Raman Tuli   +4 more
doaj   +1 more source

24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting

BMC Ophthalmology, 2017
Background To evaluate the clinical effectiveness and analyze the outcomes of a treat-and-extend (T&E) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life clinical settings over the first 2 years (24 months) of
Athanasios Vardarinos, Nitin Gupta, Raazia Janjua, Abigail Iron, Theo Empeslidis, Konstantinos T. Tsaousis   +5 more
doaj   +1 more source

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial

Ophthalmology and Therapy, 2020
Aims To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD test) between baseline and 24 months in ...
Praveen J. Patel, Hari Jayaram, Maria Eleftheriadou, Clara Vazquez-Alfageme, Niaz Islam, Gary S. Rubin, Bishwanath Pal, Peter K. Addison, Robin Hamilton, Simona Degli Esposti   +9 more
doaj   +1 more source